Ratings by Morgan Stanley (Jeffrey Hung)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/14/2026 | Contineum Therapeutics | CTNM | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Neurocrine Bio. | NBIX | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2026 | Neurocrine Bio. | NBIX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/17/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/25/2026 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2026 | Neurocrine Bio. | NBIX | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/4/2026 | BioAge Labs Inc | BIOA | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/12/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2026 | Neurocrine Bio. | NBIX | Downgrade | Equalweight (Overweight) |
137.35 (161.44) |
17.54% | Details | |
| 1/8/2026 | Contineum Therapeutics | CTNM | Downgrade | Equalweight (Overweight) |
9.49 (11.91) |
25.5% | Details | |
| 1/5/2026 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/11/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 12/5/2025 | BioAge Labs Inc | BIOA | Upgrade | Equalweight (Underweight) |
10.50 (22.32) |
112.57% | Details | |
| 11/18/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Contineum Therapeutics | CTNM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2025 | Engene Holdings Inc. | ENGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2025 | Immunocore Holdings | IMCR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/5/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2025 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/26/2025 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2025 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2025 | Engene Holdings Inc. | ENGN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/28/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Cullinan Oncology Inc. | CGEM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Contineum Therapeutics | CTNM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2025 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/8/2025 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Immunocore Holdings | IMCR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2025 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 6/11/2025 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2025 | Contineum Therapeutics | CTNM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2025 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/9/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2025 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/7/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2025 | Engene Holdings Inc. | ENGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2025 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/13/2025 | Cytokinetics | CYTK | Upgrade | Overweight (Equalweight) |
41.56 (43.27) |
4.11% | Details | |
| 2/6/2025 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2025 | Intra-Cellular Therapies | ITCI | Downgrade | Equalweight (Overweight) |
94.87 (131.87) |
39% | Details | |
| 12/20/2024 | Engene Holdings Inc. | ENGN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2024 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/13/2024 | Immuneering Corporation | IMRX | Downgrade | Underweight (Equalweight) |
2.14 (4.54) |
112.15% | Details | |
| 12/13/2024 | Immunocore Holdings | IMCR | Downgrade | Equalweight (Overweight) |
30.77 (29.20) |
-5.1% | Details | |
| 12/13/2024 | Amicus Therapeutics | FOLD | Downgrade | Equalweight (Overweight) |
10.16 (5.91) |
-41.83% | Details | |
| 12/12/2024 | PTC Therapeutics | PTCT | Upgrade | Overweight (Equalweight) |
49.67 (82.13) |
65.35% | Details | |
| 12/12/2024 | Jazz Pharmaceuticals | JAZZ | Upgrade | Overweight (Equalweight) |
120.72 (230.25) |
90.73% | Details | |
| 12/11/2024 | CervoMed | CRVO | Downgrade | Underweight (Equalweight) |
10.25 (3.72) |
-63.71% | Details | |
| 12/10/2024 | BioAge Labs Inc | BIOA | Downgrade | Underweight (Equalweight) |
20.09 (10.50) |
-47.74% | Details | |
| 11/7/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2024 | BioAge Labs Inc | BIOA | New Coverage | Overweight (N/A) |
22.99 (20.09) |
-12.61% | Details | |
| 10/15/2024 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | PTC Therapeutics | PTCT | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/26/2024 | Engene Holdings Inc. | ENGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2024 | Cullinan Oncology Inc. | CGEM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | Acadia Pharmaceuticals | ACAD | Downgrade | Equalweight (Overweight) |
18.41 (22.60) |
22.76% | Details | |
| 8/2/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/26/2024 | CervoMed | CRVO | New Coverage | Overweight (N/A) |
14.85 (3.72) |
-74.95% | Details | |
| 5/28/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | Amicus Therapeutics | FOLD | Maintain | Underweight (N/A) |
|
Details | ||
| 5/2/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/30/2024 | Cytokinetics | CYTK | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/30/2024 | Cullinan Oncology Inc. | CGEM | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2024 | Contineum Therapeutics | CTNM | New Coverage | Overweight (N/A) |
15.72 (11.91) |
-24.24% | Details | |
| 4/26/2024 | PTC Therapeutics | PTCT | Upgrade | Equalweight (Underweight) |
25.49 (49.67) |
94.86% | Details | |
| 4/17/2024 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2024 | Disc Medicine | IRON | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/15/2024 | Immuneering Corporation | IMRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/13/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2024 | Disc Medicine | IRON | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/8/2024 | Engene Holdings Inc. | ENGN | New Coverage | Overweight (N/A) |
16.01 (1.75) |
-89.07% | Details | |
| 2/20/2024 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
47.46 (65.73) |
38.5% | Details | |
| 1/16/2024 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
37.27 (35.91) |
-3.65% | Details | |
| 1/5/2024 | Cytokinetics | CYTK | Downgrade | Equalweight (Overweight) |
86.64 (41.56) |
-52.03% | Details | |
| 12/22/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Equalweight (Overweight) |
215.19 (329.83) |
53.27% | Details | |
| 12/19/2023 | Vigil Neuroscience Inc | VIGL | Downgrade | Underweight (Equalweight) |
3.60 (8.05) |
123.61% | Details | |
| 12/19/2023 | Rhythm Pharmaceuticals | RYTM | Upgrade | Overweight (Equalweight) |
47.20 (106.19) |
124.98% | Details | |
| 12/19/2023 | PTC Therapeutics | PTCT | Downgrade | Underweight (Equalweight) |
28.39 (82.13) |
189.29% | Details | |
| 12/19/2023 | Prelude Therapeutics | PRLD | Downgrade | Underweight (Equalweight) |
4.35 (4.38) |
0.69% | Details | |
| 12/19/2023 | Invivyd Inc. | IVVD | Upgrade | Equalweight (Underweight) |
1.63 (0.93) |
-42.94% | Details | |
| 12/19/2023 | Disc Medicine | IRON | Downgrade | Equalweight (Overweight) |
58.72 (70.45) |
19.98% | Details | |
| 12/19/2023 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Equalweight) |
12.72 (14.49) |
13.92% | Details | |
| 12/19/2023 | Acadia Pharmaceuticals | ACAD | Upgrade | Overweight (Equalweight) |
28.58 (18.41) |
-35.58% | Details | |
| 12/8/2023 | bluebird bio | BLUE | Upgrade | Equalweight (Underweight) |
4.83 (4.97) |
2.9% | Details | |
| 11/21/2023 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2023 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/2/2023 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/27/2023 | PTC Therapeutics | PTCT | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2023 | PTC Therapeutics | PTCT | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2023 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/20/2023 | Karuna Therapeutics Inc. | KRTX | New Coverage | Overweight (N/A) |
206.83 (329.83) |
59.47% | Details | |
| 7/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | PTC Therapeutics | PTCT | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/11/2023 | Exelixis | EXEL | New Coverage | Equalweight (N/A) |
19.31 (34.13) |
76.75% | Details | |
| 6/12/2023 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/20/2023 | Disc Medicine | IRON | New Coverage | Overweight (N/A) |
25.40 (70.45) |
177.36% | Details | |
| 4/20/2023 | Intra-Cellular Therapies | ITCI | New Coverage | Overweight (N/A) |
62.39 (94.87) |
52.06% | Details | |
| 4/19/2023 | Immuneering Corporation | IMRX | Upgrade | Equalweight (Underweight) |
12.19 (4.54) |
-62.76% | Details | |
| 4/12/2023 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/20/2023 | Esperion Therapeutics | ESPR | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/1/2023 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/28/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/27/2023 | Esperion Therapeutics | ESPR | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/27/2023 | Repare Therapeutics | RPTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/3/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/3/2023 | PTC Therapeutics | PTCT | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/3/2023 | Graphite Bio Inc | GRPH | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/3/2023 | Cullinan Oncology Inc. | CGEM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/3/2023 | Repare Therapeutics | RPTX | Downgrade | Equalweight (Overweight) |
12.60 (2.65) |
-78.97% | Details | |
| 2/3/2023 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Equalweight) |
110.22 (161.44) |
46.47% | Details | |
| 2/3/2023 | Immuneering Corporation | IMRX | Downgrade | Underweight (Equalweight) |
4.17 (4.54) |
8.87% | Details | |
| 2/3/2023 | Esperion Therapeutics | ESPR | Upgrade | Equalweight (Underweight) |
6.40 (3.16) |
-50.63% | Details | |
| 2/3/2023 | Erasca Inc | ERAS | Upgrade | Overweight (Equalweight) |
4.00 (1.57) |
-60.75% | Details | |
| 2/3/2023 | Cyteir Therapeutics | CYT | Downgrade | Underweight (Equalweight) |
1.57 (3.02) |
92.36% | Details | |
| 1/30/2023 | Celularity | CELU | Downgrade | Underweight (Equalweight) |
0.98 (0.70) |
-28.57% | Details | |
| 11/29/2022 | Cincor Pharma Inc | CINC | Downgrade | Equalweight (Overweight) |
26.53 (29.06) |
9.54% | Details | |
| 11/2/2022 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/2/2022 | Esperion Therapeutics | ESPR | Maintain | Underweight (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/13/2022 | Rubius | RUBY | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Evofem Biosciences Inc | EVFM | Maintain | Underweight (N/A) |
|
Details | ||
| 9/9/2022 | Celularity | CELU | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Bicycle Therapeutics | BCYC | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Prelude Therapeutics | PRLD | Downgrade | Equalweight (Overweight) |
7.56 (4.38) |
-42.06% | Details | |
| 9/9/2022 | Cyteir Therapeutics | CYT | Downgrade | Equalweight (Overweight) |
2.10 (3.02) |
43.81% | Details | |
| 9/9/2022 | Cincor Pharma Inc | CINC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2022 | Cincor Pharma Inc | CINC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/8/2022 | Repare Therapeutics | RPTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/15/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/11/2022 | Evofem Biosciences Inc | EVFM | Maintain | Underweight (N/A) |
|
Details | ||
| 5/11/2022 | Rubius | RUBY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/18/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/12/2022 | Evofem Biosciences Inc | EVFM | Maintain | Underweight (N/A) |
|
Details | ||
| 4/11/2022 | Rubius | RUBY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/5/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/22/2022 | Graphite Bio Inc | GRPH | Downgrade | Equalweight (Overweight) |
8.12 (3.18) |
-60.84% | Details | |
| 3/18/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/4/2022 | Evofem Biosciences Inc | EVFM | Maintain | Underweight (N/A) |
|
Details | ||
| 3/2/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/14/2022 | Bicycle Therapeutics | BCYC | New Coverage | Equalweight (N/A) |
49.02 (4.00) |
-91.84% | Details | |
| 2/11/2022 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2022 | Cincor Pharma Inc | CINC | New Coverage | Overweight (N/A) |
18.11 (29.06) |
60.46% | Details | |
| 12/7/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/24/2021 | Celularity | CELU | New Coverage | Equalweight (N/A) |
7.15 (0.70) |
-90.21% | Details | |
| 11/16/2021 | Evofem Biosciences Inc | EVFM | Maintain | Underweight (N/A) |
|
Details | ||
| 11/9/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/19/2021 | Esperion Therapeutics | ESPR | Maintain | Underweight (N/A) |
|
Details | ||
| 10/19/2021 | Rubius | RUBY | New Coverage | Equalweight (N/A) |
16.01 (0.08) |
-99.5% | Details | |
| 10/19/2021 | Insmed | INSM | New Coverage | Overweight (N/A) |
26.36 (112.89) |
328.26% | Details | |
| 10/14/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Equalweight (Overweight) |
17.63 (22.60) |
28.19% | Details | |
| 10/14/2021 | Esperion Therapeutics | ESPR | Downgrade | Underweight (Equalweight) |
10.30 (3.16) |
-69.32% | Details | |
| 10/14/2021 | Neurocrine Bio. | NBIX | Downgrade | Equalweight (Overweight) |
104.86 (161.44) |
53.96% | Details | |
| 10/14/2021 | Evofem Biosciences Inc | EVFM | Downgrade | Underweight (Equalweight) |
0.76 (0.01) |
-98.68% | Details | |
| 10/8/2021 | Prelude Therapeutics | PRLD | Upgrade | Overweight (Equalweight) |
17.34 (4.38) |
-74.74% | Details | |
| 10/8/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/8/2021 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2021 | Acceleron Pharma | XLRN | Downgrade | Equalweight (Overweight) |
175.36 (178.75) |
1.93% | Details | |
| 8/13/2021 | Repare Therapeutics | RPTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2021 | Aprea | APRE | Downgrade | Underweight (Equalweight) |
4.10 (0.83) |
-79.76% | Details | |
| 8/12/2021 | Evofem Biosciences Inc | EVFM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/10/2021 | Erasca Inc | ERAS | New Coverage | Equalweight (N/A) |
20.99 (15.07) |
-28.2% | Details | |
| 8/9/2021 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2021 | Aprea | APRE | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/4/2021 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2021 | Esperion Therapeutics | ESPR | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/20/2021 | Graphite Bio Inc | GRPH | New Coverage | Overweight (N/A) |
25.81 (8.12) |
-68.54% | Details | |
| 7/13/2021 | Cytier Therapeutics | CYT | New Coverage | Overweight (N/A) |
18.89 (3.02) |
-84.01% | Details | |
| 6/7/2021 | Cullinan Management | CGEM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/10/2021 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2021 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/5/2021 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/5/2021 | Esperion Therapeutics | ESPR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 4/27/2021 | Cullinan Management | CGEM | Upgrade | Overweight (Equalweight) |
31.49 (17.75) |
-43.63% | Details | |
| 4/6/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2021 | Prelude Therapeutics | PRLD | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/11/2021 | Esperion Therapeutics | ESPR | New Coverage | Equalweight (N/A) |
30.06 (3.16) |
-89.49% | Details | |
| 3/9/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2021 | Acceleron Pharma | XLRN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/3/2021 | Voyager Therapeutics | VYGR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 2/2/2021 | Cullinan Management | CGEM | New Coverage | Equalweight (N/A) |
38.01 (17.75) |
-53.3% | Details | |
| 12/29/2020 | Aprea | APRE | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/16/2020 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/16/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2020 | Prelude Therapeutics | PRLD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/10/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | Acceleron Pharma | XLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/22/2020 | Exelixis | exel | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/20/2020 | Acadia Pharmaceuticals | ACAD | New Coverage | Overweight (N/A) |
39.66 (22.60) |
-43.02% | Details | |
| 8/20/2020 | Evofem Biosciences Inc | EVFM | New Coverage | Equalweight (N/A) |
3.35 (0.76) |
-77.31% | Details | |
| 8/4/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2020 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2020 | Acceleron Pharma | XLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2020 | Viela Bio | VIE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2020 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/9/2020 | Cytokinetics | CYTK | Upgrade | Overweight (Equalweight) |
12.15 (80.01) |
558.52% | Details | |
| 3/4/2020 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/28/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/3/2020 | Acceleron Pharma | XLRN | Upgrade | Overweight (Equalweight) |
86.30 (175.36) |
103.2% | Details | |
| 1/17/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/17/2019 | Viela Bio | VIE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/17/2019 | Cytokinetics | CYTK | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/17/2019 | Acceleron Pharma | XLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/7/2019 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2019 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2019 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/28/2019 | Viela Bio | VIE | New Coverage | Overweight (N/A) |
19.65 (53.01) |
169.77% | Details | |
| 10/28/2019 | Aprea Therapeutics Inc. | APRE | New Coverage | Equalweight (N/A) |
25.70 (4.10) |
-84.05% | Details | |
| 10/11/2019 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2019 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2019 | Acceleron Pharma | XLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/17/2019 | Alder Biopharm | ALDR | Upgrade | Equalweight (Underweight) |
10.06 (18.88) |
87.67% | Details | |
| 8/9/2019 | Cytokinetics | CYTK | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2019 | Acceleron Pharma | XLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2019 | Acceleron Pharma | XLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/1/2019 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2019 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2019 | Cytokinetics | CYTK | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/15/2019 | Acceleron Pharma | XLRN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/12/2019 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/17/2019 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2019 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/18/2019 | Exelixis | EXEL | Upgrade | Equalweight (Underweight) |
24.76 (51.34) |
107.35% | Details | |
| 3/14/2019 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2018 | Voyager Therapeutics | VYGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2018 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2018 | Ultragenyx Pharma | RARE | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/10/2018 | Ultragenyx Pharma | RARE | New Coverage | Equalweight (N/A) |
84.40 (65.73) |
-22.12% | Details | |
| 9/10/2018 | Acceleron Pharma | XLRN | New Coverage | Equalweight (N/A) |
51.09 (178.75) |
249.87% | Details | |
| 9/10/2018 | Cytokinetics | CYTK | New Coverage | Equalweight (N/A) |
8.05 (80.01) |
893.91% | Details | |
| 9/10/2018 | Neurocrine Bio. | NBIX | New Coverage | Overweight (N/A) |
121.30 (161.44) |
33.09% | Details | |
| 9/10/2018 | Exelixis | EXEL | New Coverage | Underweight (N/A) |
18.55 (24.76) |
33.48% | Details | |
| 9/10/2018 | Alder Biopharm | ALDR | New Coverage | Underweight (N/A) |
18.10 (10.06) |
-44.42% | Details | |
| 9/10/2018 | MyoKardia | MYOK | New Coverage | Overweight (N/A) |
61.50 (224.91) |
265.71% | Details |
